Table 4.
Univariate and multivariate analyses for predicting non-recovery
| Variable | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Age | 0.552 (0.188–1.620) | 0.280 | ||
| Sex | 1.230 (0.500–3.029) | 0.552 | ||
| DM | 2.427 (0.924–6.380) | 0.072 | ||
| HTN | 1.177 (0.503–2.757) | 0.707 | ||
| CKD | 1.622 (0.520–5.056) | 0.405 | ||
| Severity of AKI (vs. stage 1 and stage 2) | ||||
| KDIGO stage 3 | 3.362 (1.192–9.482) | 0.022 | 2.468 (1.063–5.728) | 0.035 |
| Baseline eGFR | 3.129 (0.976–1.012) | 0.067 | ||
| Baseline serum creatinine | 1.058 (0.834–1.341) | 0.643 | ||
| Admission serum creatinine | 0.894 (0.732–1.092) | 0.271 | ||
| Urine NGAL/Cr | 1.013 (0.977–1.051) | 0.480 | ||
| Urine KIM-1/Cr | 1.006 (0.996 – 1.017) | 0.229 | ||
| Urine TIMP-2/IGFBP7 (vs. 1st and 2nd quartile group) | ||||
| 3rd Quartile group | 1.652 (0.524–5.210) | 0.039 | 1.896 (0.648–5.549) | 0.024 |
| 4th Quartile group | 3.361 (1.188–9.505) | 0.022 | 3.622 (1.358–9.665) | 0.010 |
In the multivariate analysis model, a backward (LR) selection approach was adopted.
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes; eGFR, estimate glomerular filtration rate; NGAL, neutrophil gelatinase-associated lipocalin; Cr, creatinine; KIM-1, kidney injury molecule 1; TIMP-2, tissue inhibitor of metalloproteinase-2; IGFBP7, insulin-like growth factor-binding protein 7.